GILEAD SCIENCES, INC. (GILD) FY2024 Q3 P&L / Income Statement

GILEAD SCIENCES, INC. (GILD) FY2024 Q3 P&L / Income Statement

Income statement for 2024-07-01 through 2024-09-30. View: Geography. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenues

7,545,000,000 US dollars

Cost of goods sold

1,574,000,000 US dollars

Gross profit (calculated)

5,971,000,000 US dollars

Operating expenses (calculated)

5,083,000,000 US dollars

Operating income (loss)

888,000,000 US dollars

Other income (expense), net (calculated)

68,000,000 US dollars

Income (loss) before income taxes

956,000,000 US dollars

Income tax (benefit) expense

negative 297,000,000 US dollars

Net income (loss)

1,253,000,000 US dollars

UNITED STATES

5,450,000,000 US dollars

Europe

1,167,000,000 US dollars

Rest of World

929,000,000 US dollars

Selling, general and administrative expenses

1,433,000,000 US dollars

Acquired in-process research and development expenses

505,000,000 US dollars

Research and development expenses

1,395,000,000 US dollars

In-process research and development impairment

1,750,000,000 US dollars

Revenue before reconciliation (calculated)

7,546,000,000 US dollars. Sum of the reported revenue categories before the separately reported reconciliation.

Components above reported revenue (calculated)

negative 1,000,000 US dollars. The disclosed components add up to more than reported revenue; this is the difference, calculated, not a reported item.

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
• Reported revenue categories plus the separately reported signed reconciliation equals consolidated revenue.